SCHEMBL4043057

SCHEMBL4043057

COc1cc(Nc2nc(N)n(-c3nc4ccccc4s3)n2)cc(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 3/20 0.58
AXL P30530 2/20 0.52
FLT3 P36888 5/20 0.48
MEN1 O00255 4/20 0.47
KMT2A Q03164 4/20 0.47
MAPK1 P28482 3/20 0.47
SMN1; SMN2 Q16637 5/20 0.46
ALDH1A1 P00352 4/20 0.46
MAPT P10636 4/20 0.46
NPC1 O15118 3/20 0.46
LMNA P02545 3/20 0.46
RAB9A P51151 3/20 0.46
NPSR1 Q6W5P4 3/20 0.46
HSP90AA1 P07900 1/20 0.46
HTT P42858 1/20 0.46
DUSP3 P51452 1/20 0.46
KDM4E B2RXH2 2/20 0.45
HPGD P15428 2/20 0.45
TDP1 Q9NUW8 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12780844 0.92 BACE1 (0.56) BACE1AXLFLT3MEN1KMT2A
SCHEMBL4042647 0.90 BACE1 (0.51) BACE1AXLFLT3MEN1KMT2A
SCHEMBL12780837 0.90 BACE1 (0.67) BACE1AXLFLT3MEN1KMT2A
SCHEMBL12780839 0.87 FLT3 (0.66) BACE1AXLFLT3MEN1KMT2A
SCHEMBL4038868 0.85 BACE1 (0.56) BACE1AXLFLT3MEN1KMT2A
SCHEMBL4045177 0.85 FLT3 (0.66) BACE1AXLFLT3MEN1KMT2A
SCHEMBL12780899 0.84 BACE1 (0.53) BACE1AXLFLT3MEN1KMT2A
SCHEMBL12779066 0.84 BACE1 (0.63) BACE1AXLFLT3MEN1KMT2A
SCHEMBL12780893 0.83 BACE1 (0.52) BACE1AXLFLT3MEN1KMT2A
SCHEMBL12780969 0.83 FLT3 (0.58) BACE1AXLFLT3MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
US-7902239-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-08 US disclosed
EP-1562589-B1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMA (US) 2009-01-07 EP disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES VERTEX PHARMACEUTICALS INCORPORATED 2008-01-17 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed
US-7279469-B2 Diaminotriazoles useful as inhibitors of protein kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080014189-A1 DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES MAP3K20, MAP3K1, MAP3K5 BACE1 3044/4885AXL 762/4885FLT3 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.